Testosterone Therapy Overprescription: Why Guidelines Matter

The Prescription Problem: Why Most Men on Testosterone Shouldn't Be

A growing body of evidence reveals a troubling pattern: testosterone therapy is prescribed inconsistently with established clinical guidelines, often to men who don't meet diagnostic thresholds or lack proper baseline investigation. This matters because testosterone replacement carries cardiovascular, hematologic, and metabolic risks that are only justified when the diagnosis is confirmed and benefits genuinely outweigh harm.

The Endocrine Society's 2018 guidelines are explicit: testosterone therapy should only be initiated in men with documented morning total testosterone <300 ng/dL (10.4 nmol/L) and clinical symptoms of hypogonadism (erectile dysfunction, low libido, fatigue, decreased muscle mass). Many prescribers skip the symptom correlation entirely or treat based on a single non-morning draw—a methodologic error that inflates prevalence estimates.

Why Baseline Labs Are Non-Negotiable

Before any testosterone replacement discussion, you need a complete endocrine panel:

Total testosterone: Draw between 7–10 AM, fasting preferred. Reference range varies by assay (typically 300–1000 ng/dL), but <300 ng/dL is the diagnostic threshold. A single low result doesn't confirm hypogonadism—repeat testing is standard.

Free testosterone: Measured by equilibrium dialysis (gold standard) or calculated from total testosterone and SHBG. Roughly 1–3% of total testosterone circulates free; the rest binds SHBG or albumin. Free testosterone may be suppressed even when total testosterone is normal—a nuance most labs miss.

LH and FSH: These reveal why testosterone is low. Primary hypogonadism (testicular failure) shows high LH/FSH with low testosterone. Secondary hypogonadism (pituitary/hypothalamic dysfunction) shows low or normal LH/FSH with low testosterone. The distinction determines whether TRT is appropriate or whether the problem lies upstream.

Prolactin: Elevated prolactin suppresses GnRH and tanked testosterone. If you have low T and high prolactin, TRT won't fix the root cause.

TSH, free T4, free T3: Hypothyroidism lowers testosterone and causes identical symptoms (fatigue, weight gain, low mood). Treating hypogonadism without addressing thyroid dysfunction is futile.

Estradiol (E2): Aromatase converts testosterone to estradiol. Overweight men with low testosterone often have elevated estradiol, increasing cardiovascular and thrombotic risk. This changes the treatment approach entirely.

DHEA-S: Dehydroepiandrosterone sulfate indicates adrenal function. Low DHEA-S with low testosterone suggests systemic endocrine dysfunction, not isolated hypogonadism.

Fasting glucose, lipid panel, hematocrit: Baseline metabolic data is essential—testosterone therapy increases hematocrit (polycythemia risk) and can worsen insulin resistance.

The Overprescription Pattern

Studies consistently show that 20–40% of men prescribed testosterone don't meet diagnostic criteria. Common reasons:

1. Symptom creep: Low energy or mild ED in men with normal testosterone gets labeled "hypogonadism."
2. Non-morning sampling: A 2 PM total testosterone of 280 ng/dL looks low, but doesn't account for circadian variation (morning levels are 25–30% higher).
3. Lab reference range confusion: Confusing "normal range" (reference range) with "optimal range" for symptom resolution.
4. Single-draw diagnosis: One low result without repeat confirmation.
5. Skipped secondary workup: No LH/FSH testing means missing secondary hypogonadism that requires different management.

What Optimal Labs Actually Look Like

For a man considering testosterone therapy:

• Total testosterone: 350–800 ng/dL (if symptomatic with lower values)
• Free testosterone: 9–30 pg/mL (optimal depends on age; younger men tolerate 15–25 pg/mL)
• LH/FSH: If low T, these should be elevated (primary) or low/normal (secondary)
• Estradiol: 15–45 pg/mL (not >60; aromatization risk increases above this)
• Prolactin: <17 ng/mL
• TSH: 0.5–2.5 mIU/L (many functional medicine practitioners optimize toward 1.0–1.5)
• Free T4: 1.0–1.7 ng/dL
• Fasting glucose: <100 mg/dL
• Hematocrit: 40–50% baseline (testosterone raises this; monitor quarterly once on therapy)

The Peptide Alternative: GH Axis Optimization

Many men diagnosed with "hypogonadism" actually have blunted GH-releasing hormone (GHRH) or growth hormone secretion. Peptides like GHRP-6, ipamorelin, or sermorelin can stimulate endogenous testosterone via LH release without exogenous replacement. This preserves testicular function and fertility—advantages TRT doesn't offer.

Keypoint: If LH/FSH are low-normal with low testosterone, GH-axis peptides + lifestyle intervention (sleep, stress, strength training, micronutrient sufficiency) should precede TRT.

Supporting Micronutrients for Testosterone Production

Baseline testing should include:

• Zinc: >100 mcg/dL. Deficiency impairs testosterone synthesis and LH signaling. Supplementation (15–30 mg/day) restores hormone production.
• Vitamin D3: 40–60 ng/mL. Calcitriol acts as a hormone; deficiency suppresses testosterone and LH.
• Magnesium: Glycinate form (400–500 mg/day) supports GABA tone and reduces cortisol, which antagonizes testosterone action.
• Selenium: 100–200 mcg/day for thyroid and antioxidant support (thyroid dysfunction lowers T).

Bottom Line

Testosterone therapy is legitimate for men with confirmed hypogonadism (low total T and low free T and elevated LH/FSH and relevant symptoms and morning sampling). Most prescriptions fail this bar. Demand baseline testing. Request the full panel—LH, FSH, prolactin, thyroid, estradiol, DHEA-S, metabolic markers. Understand reference ranges vs. optimal ranges. Consider GH-axis peptides or micronutrient repletion first. If TRT is warranted, monitor quarterly hematocrit, liver function, and lipids. Medicine is diagnosis first, treatment second—not the reverse.

Disclaimer: This content is for educational purposes only and does not constitute medical advice.